128 related articles for article (PubMed ID: 38906254)
1. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.
Fraunhoffer N; Hammel P; Conroy T; Nicolle R; Bachet JB; Harlé A; Rebours V; Turpin A; Abdelghani MB; Mitry E; Biagi J; Chanez B; Bigonnet M; Lopez A; Evesque L; Lecomte T; Assenat E; Bouché O; Renouf D; Lambert A; Monard L; Mauduit M; Cros J; Iovanna J; Dusetti N
Ann Oncol; 2024 Jun; ():. PubMed ID: 38906254
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.
Nicolle R; Bachet JB; Harlé A; Iovanna J; Hammel P; Rebours V; Turpin A; Ben Abdelghani M; Wei A; Mitry E; Lopez A; Biagi J; François E; Artru P; Lambert A; Renouf DJ; Monard L; Mauduit M; Dusetti N; Conroy T; Cros J
J Clin Oncol; 2024 Mar; 42(9):1067-1076. PubMed ID: 37963313
[TBL] [Abstract][Full Text] [Related]
3. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
Bouchart C; Navez J; Borbath I; Geboes K; Vandamme T; Closset J; Moretti L; Demetter P; Paesmans M; Van Laethem JL
BMC Cancer; 2023 Sep; 23(1):891. PubMed ID: 37735634
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC).
Kamarajah SK; Bundred JR; Alrawashdeh W; Manas D; White SA
HPB (Oxford); 2020 May; 22(5):649-659. PubMed ID: 31894014
[TBL] [Abstract][Full Text] [Related]
5. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Conroy T; Castan F; Lopez A; Turpin A; Ben Abdelghani M; Wei AC; Mitry E; Biagi JJ; Evesque L; Artru P; Lecomte T; Assenat E; Bauguion L; Ychou M; Bouché O; Monard L; Lambert A; Hammel P;
JAMA Oncol; 2022 Nov; 8(11):1571-1578. PubMed ID: 36048453
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract][Full Text] [Related]
7. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.
Nicolle R; Gayet O; Duconseil P; Vanbrugghe C; Roques J; Bigonnet M; Blum Y; Elarouci N; Armenoult L; Ayadi M; de Reyniès A; Puleo F; Augustin J; Emile JF; Svrcek M; Arsenijevic T; Hammel P; Giovannini M; Grandval P; Dahan L; Moutardier V; Gilabert M; Van Laethem JL; Bachet JB; Cros J; Iovanna J; Dusetti NJ
Ann Oncol; 2021 Feb; 32(2):250-260. PubMed ID: 33188873
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Hino K; Nishina T; Numata Y; Asagi A; Inoue T; Yoshimatsu M; Sakaguchi C; Nakasya A; Nishide N; Kajiwara T; Terao T; Nadano S; Marui K; Okujima Y; Kokubu M; Imamura Y; Kanemitsu K; Koizumi M; Kumagi T; Hiasa Y; Hyodo I
Intern Med; 2022; 61(15):2255-2261. PubMed ID: 35908959
[TBL] [Abstract][Full Text] [Related]
9. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
[TBL] [Abstract][Full Text] [Related]
10. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
Kaissis G; Ziegelmayer S; Lohöfer F; Steiger K; Algül H; Muckenhuber A; Yen HY; Rummeny E; Friess H; Schmid R; Weichert W; Siveke JT; Braren R
PLoS One; 2019; 14(10):e0218642. PubMed ID: 31577805
[TBL] [Abstract][Full Text] [Related]
11. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer.
Sawada M; Kasuga A; Mie T; Furukawa T; Taniguchi T; Fukuda K; Yamada Y; Takeda T; Kanata R; Matsuyama M; Sasaki T; Ozaka M; Sasahira N
BMC Cancer; 2020 May; 20(1):449. PubMed ID: 32434547
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer.
Gao Z; Kang SW; Erstad D; Azar J; Van Buren G; Fisher W; Sun Z; Rubinstein MP; Lee HS; Camp ER
Front Oncol; 2023; 13():1274783. PubMed ID: 38074633
[TBL] [Abstract][Full Text] [Related]
13. Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
Fu Q; Chen Y; Huang D; Guo C; Zhang X; Xiao W; Xue X; Zhang Q; Li X; Gao S; Que R; Shen Y; Wu J; Zhang M; Bai X; Liang T
Ann Surg Oncol; 2023 Aug; 30(8):5071-5080. PubMed ID: 37052821
[TBL] [Abstract][Full Text] [Related]
14. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer.
Nicolle R; Gayet O; Bigonnet M; Roques J; Chanez B; Puleo F; Augustin J; Emile JF; Svrcek M; Arsenijevic T; Hammel P; Rebours V; Giovannini M; Grandval P; Dahan L; Moutardier V; Mitry E; Van Laethem JL; Bachet JB; Cros J; Iovanna J; Dusetti NJ
Transl Oncol; 2022 Feb; 16():101315. PubMed ID: 34906890
[TBL] [Abstract][Full Text] [Related]
15. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
16. Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy.
Mortier V; Wei F; Pellat A; Marchese U; Dohan A; Brezault C; Barat M; Fuks D; Soyer P; Coriat R
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551662
[TBL] [Abstract][Full Text] [Related]
17. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Tezuka S; Ueno M; Kobayashi S; Hamaguchi T; Yamachika Y; Oishi R; Nagashima S; Fukushima T; Morimoto M; Shin M
Pancreatology; 2022 Sep; 22(6):789-796. PubMed ID: 35705458
[TBL] [Abstract][Full Text] [Related]
18. hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma.
Perera S; Jang GH; Wang Y; Kelly D; Allen M; Zhang A; Denroche RE; Dodd A; Ramotar S; Hutchinson S; Tehfe M; Ramjeesingh R; Biagi J; Lam B; Wilson J; Fischer SE; Zogopoulos G; Notta F; Gallinger S; Grant RC; Knox JJ; O'Kane GM
Clin Cancer Res; 2022 Dec; 28(23):5115-5120. PubMed ID: 36222851
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.
Delahoussaye AM; Abi Jaoude J; Green M; Fujimoto TN; Molkentine J; Garcia Garcia CJ; Gay JP; Feng N; Marszalek J; Fowlkes N; Taniguchi CM
BMC Cancer; 2022 Feb; 22(1):174. PubMed ID: 35172762
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Mie T; Sasaki T; Okamoto T; Takeda T; Mori C; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2022 Dec; 52(12):1399-1407. PubMed ID: 36111430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]